Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Lupin Limited

Revenue

Price Targets

# of Analysts

Consensus Recommendation

EBITDA

EBIT

Free Cash Flow

FFO / Share

AFFO / Share

NAV / Share

Book Value / Share

CapEx

Estimates	Mar '24 (A)	Mar '25 (A)	Mar '26 (E)
Mean	42.61	71.21	96.87
Median	42.6	71.7	96.48
Actual	41.87	71.69	—
High	46.85	75.76	116.44
Low	36.61	65.9	88
Standard Deviation	2.55	2.12	6.78
# of Estimates	30	33	36